Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04368039 · ClinicalTrials.gov registry record · NA
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
A NA study of Schizophrenia and Psychosis, sponsored by Nicholas Breitborde.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04368039 is a NA study of Schizophrenia and Psychosis that is actively recruiting participants, run by Nicholas Breitborde. The registered enrollment target is 20 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04368039, a NA study of Schizophrenia and Psychosis, is actively recruiting participants, sponsored by Nicholas Breitborde.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Conditions Studied
Interventions
- DEVICE Placebo
- DEVICE Normobaric Oxygen
Study Locations (1)
Ohio
- Harding Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2026-12-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04368039
The ClinicalTrials.gov registry entry for NCT04368039 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (91% lower). The listed sponsor is Nicholas Breitborde, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04368039 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04368039 about?
NCT04368039 is a clinical study titled "Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis". Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
What is the current status of trial NCT04368039?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2019-12-04. Estimated completion is 2026-12-07.
What conditions does trial NCT04368039 study?
This clinical trial studies the following conditions: Schizophrenia, Psychosis, First Episode Psychosis.
What interventions are being tested in trial NCT04368039?
The interventions under investigation include: Placebo (DEVICE), Normobaric Oxygen (DEVICE).
Who is sponsoring clinical trial NCT04368039?
This trial is sponsored by Nicholas Breitborde, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04368039 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.